Clinical Trials Browser

Phase 3 × Lymphoma, Non-Hodgkin × fludarabine × Clear all

NCT03480360 2026-02-19

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Phase 3 Active not recruiting

21 enrolled 19 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Lymphoma, Lymphoma, Non-Hodgkin, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell, Primary Myelofibrosis

NCT01303887 2025-04-18

PACIFICO

Phase 3 Completed

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT02406092 2024-11-21

Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

Phase 3 Completed

139 enrolled 14 charts

Lymphoma, Non-Hodgkin

NCT01456351 2024-08-22

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab

Phase 3 Completed

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT06205290 2024-04-02

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Phase 3 Withdrawn

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00577161 2020-10-05

Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

Phase 3 Withdrawn

Lymphoma, Non-Hodgkin